CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$1.45 USD
+0.07 (5.07%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $1.45 0.00 (0.00%) 4:44 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CTMX 1.45 +0.07(5.07%)
Will CTMX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CTMX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CTMX
CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
CTMX: What are Zacks experts saying now?
Zacks Private Portfolio Services
GSK Gears Up for Q1 Earnings: Here's What to Expect
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Other News for CTMX
CytomX Therapeutics (CTMX) Gets a Hold from H.C. Wainwright
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
CytomX Therapeutics Appoints Chris Ogden as New CFO
CytomX Therapeutics promotes Chris Ogden to CFO